A comparison of polymerase chain reaction and an infectivity assay for human immunodeficiency virus type 1 titration during virus inactivation of blood components

Three examples of human plasma‐derived concentrates, intermediate‐ purity factors VIII and IX, and fibrinogen were spiked with tissue culture‐grown human immunodeficiency virus type 1 (HIV‐1) strain RF. All examples were freeze‐dried and heated at 80 degrees C for 72 hours by using validated production process models. HIV‐1 infectivity was measured by a syncytial infectivity assay in C8166 cells and then compared with levels determined by nested HIV polymerase chain reaction (PCR). The infectivity assay demonstrated a reduction index of at least 4.5 log10, while PCR showed an average 1.7 log10. Large amounts of HIV‐ 1 RNA (105) were still detectable by PCR in samples in which infectivity assays failed to detect any HIV‐1. These data suggest that HIV‐1 PCR levels do not parallel HIV‐1 infectivity levels during virus‐ inactivation procedures involved in coagulation factor concentrate production. PCR was able to detect the RNA associated with inactivated HIV‐1 particles in the factor concentrates, which allows the conclusion that PCR is not a useful test with which to monitor virus‐inactivation procedures such as heating at 80 degrees C for 72 hours. This judgment contrasts with the more definite and sensitive role of PCR in diagnosing HIV‐1 infection in patients in whom a positive HIV‐1 PCR result correlates with active HIV‐1 infection and with PCR's usefulness in monitoring virus removal.

[1]  M. Busch,et al.  Resolution of infection status of human immunodeficiency virus (HIV)‐ seroindeterminate donors and high‐risk seronegative individuals with polymerase chain reaction and virus culture: absence of persistent silent HIV type 1 infection in a high‐prevalence area , 1992, Transfusion.

[2]  H. Watson,et al.  Immunological abnormalities in haemophiliacs. , 1992, Blood reviews.

[3]  H. Brackmann,et al.  Absence of human immunodeficiency virus (HIV) proviral sequences in seronegative hemophilic men and sexual partners of HIV‐seropositive hemophiliacs , 1992, Transfusion.

[4]  J. McKeating Neutralization of virus. , 1992, Methods in molecular biology.

[5]  A. Cuschieri,et al.  Effect of fibrin glues on the mechanical properties of healing wounds , 1991, The British journal of surgery.

[6]  P. Simmonds,et al.  Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. , 1991, AIDS.

[7]  C. Loveday,et al.  Detection of HIV-1 RNA in factor VIII concentrate. , 1991, AIDS.

[8]  J. Moore,et al.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization , 1991, Journal of virology.

[9]  M. Collins Practical molecular virology : viral vectors for gene expression , 1991 .

[10]  EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines. , 1991, Biologicals : journal of the International Association of Biological Standardization.

[11]  P. Simmonds,et al.  Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users , 1990, The Lancet.

[12]  P Balfe,et al.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1 , 1990 .

[13]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[14]  R. Tedder,et al.  Detection of hepatitis C viral sequences in blood donations by "nested" polymerase chain reaction and prediction of infectivity , 1990, The Lancet.

[15]  R. Tedder,et al.  Detection by PCR of hepatitis C virus in factor VIII concentrates , 1990, The Lancet.

[16]  R. Mcintosh,et al.  The effect of solution formulation on the stability and surface interactions of factor VIII during plasma fractionation , 1990 .

[17]  D. Evans,et al.  Severely Heated Therapeutic Factor VIII Concentrate of High Specific Activity , 1989, Vox sanguinis.

[18]  L. Winkelman,et al.  Severe heat treatment of lyophilised coagulation factors. , 1989, Current studies in hematology and blood transfusion.

[19]  A. Macleod,et al.  Viral inactivation strategies for monoclonal antibodies: dry heating , 1989 .

[20]  A. Dalgleish,et al.  Quantitation of HIV-1 activity in tissue culture supernatants: effects of culture condition on syncytial assays and virus production. , 1989, Journal of virological methods.

[21]  C. Prowse,et al.  Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs , 1987, British journal of haematology.

[22]  R. Mcintosh,et al.  A HIGH-YIELD FACTOR VIII CONCENTRATE SUITABLE FOR ADVANCED HEAT TREATMENT , 1987, Thrombosis and Haemostasis.

[23]  H. Geiger,et al.  A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus. , 1987, Journal of biological standardization.

[24]  A. Prince,et al.  EFFECT OF HEAT TREATMENT OF LYOPHILISED BLOOD DERIVATIVES ON INFECTIVITY OF HUMAN IMMUNODEFICIENY , 1986, The Lancet.

[25]  M. Wiebe,et al.  Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinations , 1985, Transfusion.

[26]  M. Wiebe,et al.  Inactivation of viruses in labile blood derivatives. II. Physical methods , 1985, Transfusion.

[27]  P. Mannucci,et al.  TRANSMISSION OF NON-A, NON-B HEPATITIS BY HEAT-TREATED FACTOR VIII CONCENTRATE , 1985, The Lancet.

[28]  S. Middleton,et al.  A Therapeutic Concentrate of Coagulation Factors II, IX and X from Citrated, Factor VIII‐Depleted Plasma , 1973, Vox sanguinis.

[29]  R. Hardisty,et al.  A One-stage Factor VIII (Antihaemophilic Globulin) Assay and its Use on Venous and Capillary Plasma , 1962, Thrombosis and Haemostasis.